Cargando…
The performance of plasma amyloid beta measurements in identifying amyloid plaques in Alzheimer’s disease: a literature review
The extracellular buildup of amyloid beta (Aβ) plaques in the brain is a hallmark of Alzheimer’s disease (AD). Detection of Aβ pathology is essential for AD diagnosis and for identifying and recruiting research participants for clinical trials evaluating disease-modifying therapies. Currently, AD di...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9793600/ https://www.ncbi.nlm.nih.gov/pubmed/36575454 http://dx.doi.org/10.1186/s13195-022-01117-1 |
_version_ | 1784859875743891456 |
---|---|
author | Brand, Abby L. Lawler, Paige E. Bollinger, James G. Li, Yan Schindler, Suzanne E. Li, Melody Lopez, Samir Ovod, Vitaliy Nakamura, Akinori Shaw, Leslie M. Zetterberg, Henrik Hansson, Oskar Bateman, Randall J. |
author_facet | Brand, Abby L. Lawler, Paige E. Bollinger, James G. Li, Yan Schindler, Suzanne E. Li, Melody Lopez, Samir Ovod, Vitaliy Nakamura, Akinori Shaw, Leslie M. Zetterberg, Henrik Hansson, Oskar Bateman, Randall J. |
author_sort | Brand, Abby L. |
collection | PubMed |
description | The extracellular buildup of amyloid beta (Aβ) plaques in the brain is a hallmark of Alzheimer’s disease (AD). Detection of Aβ pathology is essential for AD diagnosis and for identifying and recruiting research participants for clinical trials evaluating disease-modifying therapies. Currently, AD diagnoses are usually made by clinical assessments, although detection of AD pathology with positron emission tomography (PET) scans or cerebrospinal fluid (CSF) analysis can be used by specialty clinics. These measures of Aβ aggregation, e.g. plaques, protofibrils, and oligomers, are medically invasive and often only available at specialized medical centers or not covered by medical insurance, and PET scans are costly. Therefore, a major goal in recent years has been to identify blood-based biomarkers that can accurately detect AD pathology with cost-effective, minimally invasive procedures. To assess the performance of plasma Aβ assays in predicting amyloid burden in the central nervous system (CNS), this review compares twenty-one different manuscripts that used measurements of 42 and 40 amino acid-long Aβ (Aβ42 and Aβ40) in plasma to predict CNS amyloid status. Methodologies that quantitate Aβ42 and 40 peptides in blood via immunoassay or immunoprecipitation-mass spectrometry (IP-MS) were considered, and their ability to distinguish participants with amyloidosis compared to amyloid PET and CSF Aβ measures as reference standards was evaluated. Recent studies indicate that some IP-MS assays perform well in accurately and precisely measuring Aβ and detecting brain amyloid aggregates. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13195-022-01117-1. |
format | Online Article Text |
id | pubmed-9793600 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-97936002022-12-28 The performance of plasma amyloid beta measurements in identifying amyloid plaques in Alzheimer’s disease: a literature review Brand, Abby L. Lawler, Paige E. Bollinger, James G. Li, Yan Schindler, Suzanne E. Li, Melody Lopez, Samir Ovod, Vitaliy Nakamura, Akinori Shaw, Leslie M. Zetterberg, Henrik Hansson, Oskar Bateman, Randall J. Alzheimers Res Ther Review The extracellular buildup of amyloid beta (Aβ) plaques in the brain is a hallmark of Alzheimer’s disease (AD). Detection of Aβ pathology is essential for AD diagnosis and for identifying and recruiting research participants for clinical trials evaluating disease-modifying therapies. Currently, AD diagnoses are usually made by clinical assessments, although detection of AD pathology with positron emission tomography (PET) scans or cerebrospinal fluid (CSF) analysis can be used by specialty clinics. These measures of Aβ aggregation, e.g. plaques, protofibrils, and oligomers, are medically invasive and often only available at specialized medical centers or not covered by medical insurance, and PET scans are costly. Therefore, a major goal in recent years has been to identify blood-based biomarkers that can accurately detect AD pathology with cost-effective, minimally invasive procedures. To assess the performance of plasma Aβ assays in predicting amyloid burden in the central nervous system (CNS), this review compares twenty-one different manuscripts that used measurements of 42 and 40 amino acid-long Aβ (Aβ42 and Aβ40) in plasma to predict CNS amyloid status. Methodologies that quantitate Aβ42 and 40 peptides in blood via immunoassay or immunoprecipitation-mass spectrometry (IP-MS) were considered, and their ability to distinguish participants with amyloidosis compared to amyloid PET and CSF Aβ measures as reference standards was evaluated. Recent studies indicate that some IP-MS assays perform well in accurately and precisely measuring Aβ and detecting brain amyloid aggregates. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13195-022-01117-1. BioMed Central 2022-12-27 /pmc/articles/PMC9793600/ /pubmed/36575454 http://dx.doi.org/10.1186/s13195-022-01117-1 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Review Brand, Abby L. Lawler, Paige E. Bollinger, James G. Li, Yan Schindler, Suzanne E. Li, Melody Lopez, Samir Ovod, Vitaliy Nakamura, Akinori Shaw, Leslie M. Zetterberg, Henrik Hansson, Oskar Bateman, Randall J. The performance of plasma amyloid beta measurements in identifying amyloid plaques in Alzheimer’s disease: a literature review |
title | The performance of plasma amyloid beta measurements in identifying amyloid plaques in Alzheimer’s disease: a literature review |
title_full | The performance of plasma amyloid beta measurements in identifying amyloid plaques in Alzheimer’s disease: a literature review |
title_fullStr | The performance of plasma amyloid beta measurements in identifying amyloid plaques in Alzheimer’s disease: a literature review |
title_full_unstemmed | The performance of plasma amyloid beta measurements in identifying amyloid plaques in Alzheimer’s disease: a literature review |
title_short | The performance of plasma amyloid beta measurements in identifying amyloid plaques in Alzheimer’s disease: a literature review |
title_sort | performance of plasma amyloid beta measurements in identifying amyloid plaques in alzheimer’s disease: a literature review |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9793600/ https://www.ncbi.nlm.nih.gov/pubmed/36575454 http://dx.doi.org/10.1186/s13195-022-01117-1 |
work_keys_str_mv | AT brandabbyl theperformanceofplasmaamyloidbetameasurementsinidentifyingamyloidplaquesinalzheimersdiseasealiteraturereview AT lawlerpaigee theperformanceofplasmaamyloidbetameasurementsinidentifyingamyloidplaquesinalzheimersdiseasealiteraturereview AT bollingerjamesg theperformanceofplasmaamyloidbetameasurementsinidentifyingamyloidplaquesinalzheimersdiseasealiteraturereview AT liyan theperformanceofplasmaamyloidbetameasurementsinidentifyingamyloidplaquesinalzheimersdiseasealiteraturereview AT schindlersuzannee theperformanceofplasmaamyloidbetameasurementsinidentifyingamyloidplaquesinalzheimersdiseasealiteraturereview AT limelody theperformanceofplasmaamyloidbetameasurementsinidentifyingamyloidplaquesinalzheimersdiseasealiteraturereview AT lopezsamir theperformanceofplasmaamyloidbetameasurementsinidentifyingamyloidplaquesinalzheimersdiseasealiteraturereview AT ovodvitaliy theperformanceofplasmaamyloidbetameasurementsinidentifyingamyloidplaquesinalzheimersdiseasealiteraturereview AT nakamuraakinori theperformanceofplasmaamyloidbetameasurementsinidentifyingamyloidplaquesinalzheimersdiseasealiteraturereview AT shawlesliem theperformanceofplasmaamyloidbetameasurementsinidentifyingamyloidplaquesinalzheimersdiseasealiteraturereview AT zetterberghenrik theperformanceofplasmaamyloidbetameasurementsinidentifyingamyloidplaquesinalzheimersdiseasealiteraturereview AT hanssonoskar theperformanceofplasmaamyloidbetameasurementsinidentifyingamyloidplaquesinalzheimersdiseasealiteraturereview AT batemanrandallj theperformanceofplasmaamyloidbetameasurementsinidentifyingamyloidplaquesinalzheimersdiseasealiteraturereview AT brandabbyl performanceofplasmaamyloidbetameasurementsinidentifyingamyloidplaquesinalzheimersdiseasealiteraturereview AT lawlerpaigee performanceofplasmaamyloidbetameasurementsinidentifyingamyloidplaquesinalzheimersdiseasealiteraturereview AT bollingerjamesg performanceofplasmaamyloidbetameasurementsinidentifyingamyloidplaquesinalzheimersdiseasealiteraturereview AT liyan performanceofplasmaamyloidbetameasurementsinidentifyingamyloidplaquesinalzheimersdiseasealiteraturereview AT schindlersuzannee performanceofplasmaamyloidbetameasurementsinidentifyingamyloidplaquesinalzheimersdiseasealiteraturereview AT limelody performanceofplasmaamyloidbetameasurementsinidentifyingamyloidplaquesinalzheimersdiseasealiteraturereview AT lopezsamir performanceofplasmaamyloidbetameasurementsinidentifyingamyloidplaquesinalzheimersdiseasealiteraturereview AT ovodvitaliy performanceofplasmaamyloidbetameasurementsinidentifyingamyloidplaquesinalzheimersdiseasealiteraturereview AT nakamuraakinori performanceofplasmaamyloidbetameasurementsinidentifyingamyloidplaquesinalzheimersdiseasealiteraturereview AT shawlesliem performanceofplasmaamyloidbetameasurementsinidentifyingamyloidplaquesinalzheimersdiseasealiteraturereview AT zetterberghenrik performanceofplasmaamyloidbetameasurementsinidentifyingamyloidplaquesinalzheimersdiseasealiteraturereview AT hanssonoskar performanceofplasmaamyloidbetameasurementsinidentifyingamyloidplaquesinalzheimersdiseasealiteraturereview AT batemanrandallj performanceofplasmaamyloidbetameasurementsinidentifyingamyloidplaquesinalzheimersdiseasealiteraturereview |